EX-10.10: Re: Supply And Distribution Agreement: Investigational Phase between Omrix biopharmaceuticals, Ltd. and FFF Enterprises, Inc., dated as of December 21, 2005 (the "Agreement")

<PAGE>

                                                                   Exhibit 10.10

                                             (OMRIX BIOPHARMACEUTICALS(TM) LOGO)
                                                    innovative solutions
                                                     for a healthier world

August 10, 2006

Mr. Patrick Schmidt
FFF Enterprises, Inc.
41093 County Center Drive
Temecula, CA 92651

     Re: Supply And Distribution Agreement: Investigational Phase between Omrix
          biopharmaceuticals, Ltd. and FFF Enterprises, Inc., dated as of
         December 21, 2005 (the "Agreement")

Dear Pat:

To date, the FDA has not approved the Treatment Protocol and the Treatment
Protocol Charge Price for Omrigam NF. Nevertheless, FFF and Omrix have agreed to
conduct the Phase 3 Clinical Trial in accordance with Section 4.2.c.2 of the
Agreement, as modified by the following terms:

     1.    FFF commits to complete the Phase 3 Clinical Trial independent of
          receiving an approval for the Treatment Protocol and Treatment
          Protocol Charge Price.

     2.    FFF will continue to attempt to obtain approval from the FDA for
          Treatment Protocol and Treatment Protocol Charge Price during the
          Phase 3 Clinical Trial.

     3.    Omrix commits to supply FFF with Omrigam NF manufactured from source
          plasma in the amount required for the Phase 3 Clinical Trial.

     4.    Omrix will invoice and FFF will pay the Treatment Protocol Purchase
          Price (*** per gram) for the Omrigam NF supplied for the purpose of
          the Phase 3 Clinical Trial. FFF will pay this amount notwithstanding
          the provisions of Section 4.3.a of the Agreement. Payment will be due
          within 30 days from the date of shipping. The cost of purchasing
          Omrigam NF under this letter shall not be included in the calculation
          of FFF's out-of-pocket expenses for conducting the Clinical Trials
          under Section 15.3.a of the Agreement.

     5.    If FFF receives approval of a Treatment Protocol from the FDA, Omrix
          will credit FFF for the Treatment Protocol Purchase Price charged by
          Omrix for Omrigam NF supplied by Omrix for